A New Biomarker for Muscle Degeneration in Pompe Disease
A study published in the Journal of Neurology, Neurosurgery & Psychiatry demonstrates that high muscle glycogen levels, measured using advanced 7 Tesla 13C-MR Spectroscopy, precede the characteristic fatty degeneration seen in late-onset Pompe disease. Researchers found that patients had significantly elevated glycogen concentrations in the hamstring, lumbar, and anterior thigh muscles compared to healthy controls, while calf muscle levels were similar. This cross-sectional analysis suggests that glycogen accumulation is an early event in the disease process, potentially offering a quantifiable target for monitoring treatment efficacy before irreversible structural damage occurs.
Why it might matter to you: For critical care specialists managing complex metabolic and neuromuscular disorders, this research introduces a potential early biomarker for disease progression. Monitoring glycogen levels could refine the assessment of therapeutic interventions, moving beyond late-stage anatomical changes to earlier, reversible metabolic ones. This approach aligns with the critical care imperative for precise, dynamic monitoring to guide therapy and improve outcomes in patients with multi-organ involvement.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
